The Korean Journal of Medicine

  • 제84권4호
  • /
  • Pages.562-566
  • /
  • 2013
  • /
  • 1738-9364(pISSN)
  • /
  • 2289-0769(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

Abciximab 치료 후 급성 미만성 폐포출혈이 발생한 1예

A Case of Diffuse Alveolar Hemorrhage Following Abciximab Therapy

  • Ryu, Han Jun (Department of Internal Medicine, Daegu Fatima Hospital) ;
  • Jung, Yeoun-Su (Department of Internal Medicine, Daegu Fatima Hospital) ;
  • Kim, Min-Hee (Department of Internal Medicine, Daegu Fatima Hospital) ;
  • Jung, Ho-Jin (Department of Internal Medicine, Daegu Fatima Hospital) ;
  • Jung, Byung-Chun (Department of Internal Medicine, Daegu Fatima Hospital) ;
  • Lee, Bong-Ryeol (Department of Internal Medicine, Daegu Fatima Hospital) ;
  • Kang, Hyun-Jae (Department of Internal Medicine, Daegu Fatima Hospital)
  • 투고 : 2012.04.23
  • 심사 : 2012.06.29
  • 발행 : 2013.04.01
⟨ 이전 논문 다음 논문 ⟩

초록

Abciximab은 급성관상동맥 증후군 환자에서 허혈성 합병증을 줄이는 효과가 있다는 것이 알려져 있다. 그러나 뇌출혈, 카테터 삽입 부위의 출혈등의 출혈성 부작용이 발생할 수 있다. 급성 미만성 폐포출혈의 경우 그 빈도가 드물다고 알려져 있으나 환자에게 치명적이며 진단이 어려운 경우가 많다. 또한 아직까지 국내에서는 이에 대한 보고가 없으며 위험인자 등에 대해서도 뚜렷하게 알려져 있지 않다. 저자들은 급성 관상 동맥 증후군 환자에게서 abcximab 사용 후 급성 미만성 페포출혈이 발생한 1예를 경험하였기에 보고하는 바이다.

Platelets play an important role in the development of acute coronary syndrome. Platelet-inhibiting drugs, such as glycoprotein IIb/IIIa inhibitors, can be beneficial when they are administered at the time of primary percutaneous coronary intervention for acute coronary syndrome. Although an increased risk for bleeding complications is well recognized, the risk associated with diffuse alveolar hemorrhage is much less reported. We report a case of diffuse alveolar hemorrhage after using abciximab.

키워드

참고문헌

  1. Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months: the EPIC Investigators. Lancet 1994;343: 881-886. https://doi.org/10.1016/S0140-6736(94)90007-8
  2. Aguirre FV, Topol EJ, Ferguson JJ, et al. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention: EPIC Investigators. Circulation 1995; 91:2882-2890. https://doi.org/10.1161/01.CIR.91.12.2882
  3. Sitges M, Villa FP. Massive pulmonary hemorrhage in a patient treated with a platelet glycoprotein IIb/IIIa inhibitor. Int J Cardiol 1997;62:269-271. https://doi.org/10.1016/S0167-5273(97)00228-3
  4. Platelet glycoprotein IIb/IIIa receptor blockade and lowdose heparin during percutaneous coronary revascularization: the EPILOG Investigators. N Engl J Med 1997;336: 1689-1696. https://doi.org/10.1056/NEJM199706123362401
  5. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997;349:1429-1435. https://doi.org/10.1016/S0140-6736(96)10452-9
  6. EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352:87-92. https://doi.org/10.1016/S0140-6736(98)85010-1
  7. Ali A, Hashem M, Rosman HS, Kazmouz G, Gardin JM, Schrieber TL. Use of platelet glycoprotein IIb/IIIa inhibitors and spontaneous pulmonary hemorrhage. J Invasive Cardiol 2003;15:186-188.
  8. Lara AR, Schwarz MI. Diffuse alveolar hemorrhage. Chest 2010;137:1164-1171. https://doi.org/10.1378/chest.08-2084
  9. Nikolsky E, Mehran R, Dangas G, et al. Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. Eur Heart J 2007;28:1936-1945. https://doi.org/10.1093/eurheartj/ehm194
  10. Ener RA, Bruno N, Dadourian D, et al. Alveolar hemorrhage associated with platelet glycoprotein IIb/IIIa receptor inhibitors. J Invasive Cardiol 2006;18:254-261.

피인용 문헌

  1. Heart-lung transplantation for refractory diffuse alveolar hemorrhage supported by prolonged extracorporeal membrane oxygenation after cardiogenic shock from ST segment elevation myocardial infarction vol.35, pp.8, 2013, https://doi.org/10.1177/0267659120915396